Exelixis, INC.: management transactions · United States · SEC (Form 4)

About Exelixis, INC.

Exelixis, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker EXEL in the United States, with a business model firmly anchored in oncology. Founded in 1994 and headquartered in Alameda, California, in the Bay Area, the company evolved from a genomics-oriented drug discovery platform into an integrated biopharma organization spanning research, clinical development, regulatory execution, and commercialization. The company’s name, derived from the Greek word “Exelixi” meaning evolution, captures that strategic transformation. ([exelixis.com](https://www.exelixis.com/our-story/?utm_source=openai)) Exelixis’ commercial engine today is built around the cabozantinib franchise, marketed in the U.S. as CABOMETYX, with COMETRIQ also part of the portfolio in certain indications. These products address difficult-to-treat cancers, including renal cell carcinoma, thyroid cancer, and, more recently, neuroendocrine tumors. Beyond the existing franchise, Exelixis is advancing zanzalintinib, a next-generation candidate intended to build on the clinical profile of cabozantinib while improving key pharmacokinetic characteristics. ([ir.exelixis.com](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-us-fda-approval-cabometyxr-cabozantinib-4?utm_source=openai)) From a competitive standpoint, Exelixis stands out by combining meaningful commercial revenues with a late-stage development pipeline. Management is explicitly working to establish a second commercial oncology franchise around zanzalintinib, with advanced programs in metastatic colorectal cancer, meningioma, and other solid tumors. Recent developments underscore that strategy: the company expanded its GI sales organization, the FDA accepted the NDA for zanzalintinib in previously treated metastatic colorectal cancer, and new clinical studies were initiated in 2026. ([ir.exelixis.com](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-first-quarter-2026-financial-results-and?utm_source=openai)) Geographically, Exelixis remains primarily a U.S. company, with its main operational and commercial base in the United States. That said, the company also has meaningful international reach through partnerships with Ipsen and Takeda for certain ex-U.S. and Japan rights related to cabozantinib. This structure allows Exelixis to monetize global demand while retaining strategic control over its core assets. ([ir.exelixis.com](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-us-fda-approval-cabometyxr-cabozantinib-0?utm_source=openai)) Recent highlights include strong 2025 and early-2026 financial updates, continued cabozantinib franchise growth, new clinical trial starts, and active U.S. regulatory review for zanzalintinib in colorectal cancer. Exelixis has also continued share repurchases, signaling an active capital-return policy. For investors, the name represents a NASDAQ-listed healthcare company with an established revenue base, a substantial oncology pipeline, and multiple near- to medium-term catalysts tied to clinical readouts and regulatory milestones. ([ir.exelixis.com](https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-first-quarter-2026-financial-results-and?utm_source=openai))